Jul 29, 2025 07:00AM
Jun 20, 2025 04:31PM
Jun 20, 2025 04:30PM
Dec 11, 2024 09:44AM
Aug 15, 2024 08:57AM
Feb 27, 2024 04:11PM
Feb 27, 2024 04:08PM Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Feb 7, 2023 07:00AM
Nov 1, 2022 07:00AM
Aug 2, 2022 07:00AM
May 5, 2022 08:15AM
May 3, 2022 01:25PM
May 3, 2022 07:00AM
Mar 26, 2022 10:40AM Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
Mar 14, 2022 08:02AM
Mar 14, 2022 08:00AM
Feb 8, 2022 07:00AM
Dec 14, 2021 04:31PM
Dec 14, 2021 04:30PM
Nov 2, 2021 07:00AM
Nov 1, 2021 07:03AM Incyte (INCY) Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
Nov 1, 2021 07:00AM
Sep 1, 2021 12:36PM
Aug 3, 2021 07:00AM
Jul 16, 2021 10:01AM
Jul 16, 2021 10:00AM
Jul 14, 2021 05:02PM
Jul 14, 2021 05:00PM Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease
Jun 24, 2021 03:30PM
Jun 24, 2021 03:30PM
Jun 22, 2021 12:38PM
Jun 11, 2021 10:23AM
Jun 11, 2021 07:30AM
Jun 11, 2021 07:30AM
Jun 8, 2021 07:32AM Incyte (INCY) Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi) Chronic Graft-Versus-Host Disease
Jun 8, 2021 07:30AM
May 4, 2021 07:00AM
Apr 6, 2021 04:30PM
Apr 6, 2021 04:30PM
Mar 9, 2021 07:48AM
Feb 22, 2021 08:06AM
Feb 22, 2021 08:00AM Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
Feb 19, 2021 08:02AM
Feb 19, 2021 08:00AM
Jan 21, 2021 04:33PM
Jan 21, 2021 04:30PM
Dec 29, 2020 07:42AM
May 5, 2020 07:00AM
Apr 21, 2020 07:07AM Incyte (INCY) PT Raised to $112 at Oppenheimer on Pemazyre Noting 5 Upcoming Catalysts
Mar 3, 2020 04:30PM

15,414 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All